ALK Positive Lung Cancer Treatment Market by Drugs (Crizotinib, Alectinib, Ceritinib, and Brigatinib), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Clinics), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026

ALK positive lung cancer treatment is used for people suffering from lung cancer with Anaplastic Lymphoma Kinase (ALK) mutation (the EML4-ALK fusion gene). This gene mutation is due to gene rearrangement by fusion of two genes called as ALK and Echinoderm Microtubule-associated protein Like 4 (EML4). The ALK gene fusion was first reported in 2007, in Non-small cell lung cancer (NSCLC) patients.

ALK Positive Lung Cancer Treatment Market Drivers

New drug approvals for treatment of ALK positive lung cancer is expected to drive growth of the market. For instance, in August 2018, China National Drug Administration (CNDA) approved Alecensa (alectinib) of F. Hoffmann-La Roche Ltd., for treatment of ALK-positive lung cancer. Moreover, CNDA granted marketing authorization for Alecensa (alectinib), as monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive and advanced non-small cell lung cancer (NSCLC).

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2201

ALK Positive Lung Cancer Treatment Market Restraints

Development of rapid resistance to drugs is expected to limit growth of the ALK positive lung cancer treatment market. For instance, according to an Oncology Live February 2018 report, major challenge in drug development is rapid growth in resistance, which is responsible for slow patient recovery from disease. Moreover, according to an article published in Cancers journal, in August 2017, the mechanisms for resistance in drugs is tyrosine kinase mutations, and Epidermal Growth Factor Receptor (EGFR) activation. These bypass mechanisms of resistance are aggravating tumor cells, which in turn is restraining growth of the market.

ALK Positive Lung Cancer Treatment Market – Regional Analysis

On the basis of region, the global ALK positive lung cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America region is expected to witness significant growth in the market, owing to increasing number of clinical trials operating in the U.S. For instance, TP Therapeutics, Inc., is undergoing clinical trial for TPX-0005 drug for treating ALK mutations. The study is expected to complete in December 2021.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/alk-positive-lung-cancer-treatment-market-2201

Asia Pacific region is expected to witness the significant growth in the market, owing to increasing use of tobacco and smoking leading to lung cancer. According to an article published in Eastern Journal of medical Sciences 2017, lung cancer contributes around 6.8% of all cancers in India, representing the significant burden of lung cancer on country, which is contributing towards the cancer morbidity and mortality.

Key players operating in ALK positive lung cancer treatment market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, TP Therapeutics, Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2201

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737